

AMBU APPOINTS HEAD OF INVESTOR RELATIONS

Lisa Bedell Clive brings 25 years of capital markets experience to Ambu, including two decades at leading investment research firm Bernstein covering the European MedTech sector.

Copenhagen, Denmark, 18 August 2026 – Ambu, the global leader in single-use endoscopy, today announces the appointment of Lisa Bedell Clive as its new Head of Investor Relations, effective immediately.

Lisa joins Ambu with 25 years of capital markets experience and an extensive track record in the global healthcare sector. For the past two decades, she has been with Bernstein, one of the world's leading investment research and brokerage firms, where she most recently served as Senior Research Analyst, covering the European Medical Devices & Services sector.

Through strong industry research, deep medical device sector expertise, and close engagement with healthcare company executives, key opinion leaders, and institutional investors, Lisa has earned a reputation as one of Europe's leading healthcare analysts.

"I'm very pleased to welcome Lisa to Ambu", says Henrik Skak Bender, Chief Financial Officer of Ambu. "She is a highly respected voice in the MedTech investor community and brings a strong combination of capital markets expertise, industry insight, and investor relationships. Drawing on two decades of experience analyzing global MedTech companies, Lisa understands what drives long-term value creation in MedTech and the opportunities ahead of Ambu. She will play an instrumental role as we continue to strengthen our engagement with investors and execute on Ambu's next phase of growth."

Lisa grew up in the United States but has spent most of her professional life in London, giving her a unique perspective on the global healthcare landscape. In addition to her broad MedTech industry expertise, she is recognized for her insights into emerging healthcare trends, including artificial intelligence, and the shift toward value-based care.

"I'm thrilled to be joining Ambu at such an exciting time, as the company reshapes the global endoscopy market for the benefit of patients, clinicians, and health systems," says Lisa Bedell Clive, incoming Head of IR at Ambu. "After two decades as a sell-side MedTech analyst, joining Ambu is a natural next step. Ambu stands out as one of the most compelling growth stories in MedTech, combining leadership in single-use endoscopy with a proven ability to expand and develop its end-markets. I look forward to helping investors understand how Ambu's strategy, technological edge, and market-development capabilities translate into durable, profitable growth."



Ambu A/S
Baltorpbakken 13
2750 Ballerup
Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.Ambu.com

Media
Tine Bjørn Schmidt
Director of Corporate Communications
tisc@ambu.com
+45 2264 0697

Investors
Frederik Futtrup
Associate, Investor Relations
frfu@ambu.com
+45 6070 9526

ABOUT AMBU

Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.

For more information, please visit Ambu.com.